These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 16556246

  • 1. Headache prevention outcome and body mass index.
    Bigal ME, Gironda M, Tepper SJ, Feleppa M, Rapoport AM, Sheftell FD, Lipton RB.
    Cephalalgia; 2006 Apr; 26(4):445-50. PubMed ID: 16556246
    [Abstract] [Full Text] [Related]

  • 2. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 3. Obesity and migraine: a population study.
    Bigal ME, Liberman JN, Lipton RB.
    Neurology; 2006 Feb 28; 66(4):545-50. PubMed ID: 16354886
    [Abstract] [Full Text] [Related]

  • 4. Depression and anxiety: effect on the migraine-obesity relationship.
    Tietjen GE, Peterlin BL, Brandes JL, Hafeez F, Hutchinson S, Martin VT, Dafer RM, Aurora SK, Stein MR, Herial NA, Utley C, White L, Khuder SA.
    Headache; 2007 Jun 28; 47(6):866-75. PubMed ID: 17578537
    [Abstract] [Full Text] [Related]

  • 5. Body mass index and episodic headaches: a population-based study.
    Bigal ME, Tsang A, Loder E, Serrano D, Reed ML, Lipton RB.
    Arch Intern Med; 2007 Oct 08; 167(18):1964-70. PubMed ID: 17923596
    [Abstract] [Full Text] [Related]

  • 6. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study.
    Buse D, Manack A, Serrano D, Reed M, Varon S, Turkel C, Lipton R.
    Headache; 2012 Jan 08; 52(1):3-17. PubMed ID: 22106869
    [Abstract] [Full Text] [Related]

  • 7. Influence of obesity on progression of non-diabetic chronic kidney disease: a retrospective cohort study.
    Othman M, Kawar B, El Nahas AM.
    Nephron Clin Pract; 2009 Jan 08; 113(1):c16-23. PubMed ID: 19590231
    [Abstract] [Full Text] [Related]

  • 8. Post-traumatic stress disorder in episodic and chronic migraine.
    Peterlin BL, Tietjen G, Meng S, Lidicker J, Bigal M.
    Headache; 2008 Apr 08; 48(4):517-22. PubMed ID: 18377377
    [Abstract] [Full Text] [Related]

  • 9. The relationship of excess body weight and health-related quality of life: evidence from a population study in Taiwan.
    Huang IC, Frangakis C, Wu AW.
    Int J Obes (Lond); 2006 Aug 08; 30(8):1250-9. PubMed ID: 16520814
    [Abstract] [Full Text] [Related]

  • 10. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: a case series.
    Novack V, Fuchs L, Lantsberg L, Kama S, Lahoud U, Horev A, Loewenthal N, Ifergane G.
    Cephalalgia; 2011 Oct 08; 31(13):1336-42. PubMed ID: 21700645
    [Abstract] [Full Text] [Related]

  • 11. Prospective assessment of axial back pain symptoms before and after bariatric weight reduction surgery.
    Khoueir P, Black MH, Crookes PF, Kaufman HS, Katkhouda N, Wang MY.
    Spine J; 2009 Jun 08; 9(6):454-63. PubMed ID: 19356988
    [Abstract] [Full Text] [Related]

  • 12. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM, Berber A, Macias-Lara CC, Lucio-Ortiz C, Del-Rio-Navarro BE, Dorantes-Alvárez LM.
    Clin Ther; 2006 May 08; 28(5):770-82. PubMed ID: 16861099
    [Abstract] [Full Text] [Related]

  • 13. Body mass index in middle age and health-related quality of life in older age: the Chicago heart association detection project in industry study.
    Daviglus ML, Liu K, Yan LL, Pirzada A, Garside DB, Schiffer L, Dyer AR, Greenland P, Stamler J.
    Arch Intern Med; 2003 Nov 10; 163(20):2448-55. PubMed ID: 14609781
    [Abstract] [Full Text] [Related]

  • 14. Migraine days decline with duration of illness in adolescents with transformed migraine.
    Bigal ME, Sheftell FD, Tepper SJ, Rapoport AM, Lipton RB.
    Cephalalgia; 2005 Jul 10; 25(7):482-7. PubMed ID: 15955034
    [Abstract] [Full Text] [Related]

  • 15. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ, Gladstone JP, Lewis S, Rogers R, Dodick DW.
    Headache; 2005 Apr 10; 45(4):308-14. PubMed ID: 15836566
    [Abstract] [Full Text] [Related]

  • 16. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr 10; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 17. Field testing alternative criteria for chronic migraine.
    Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB.
    Cephalalgia; 2006 Apr 10; 26(4):477-82. PubMed ID: 16556250
    [Abstract] [Full Text] [Related]

  • 18. Migraine changes with age: IMPACT on migraine classification.
    Kelman L.
    Headache; 2006 Apr 10; 46(7):1161-71. PubMed ID: 16866720
    [Abstract] [Full Text] [Related]

  • 19. Correlation of increase in phosphene threshold with reduction of migraine frequency: observation of levetiracetam-treated subjects.
    Young W, Shaw J, Bloom M, Gebeline-Myers C.
    Headache; 2008 Apr 10; 48(10):1490-8. PubMed ID: 19076647
    [Abstract] [Full Text] [Related]

  • 20. Obesity paradox in patients with hypertension and coronary artery disease.
    Uretsky S, Messerli FH, Bangalore S, Champion A, Cooper-Dehoff RM, Zhou Q, Pepine CJ.
    Am J Med; 2007 Oct 10; 120(10):863-70. PubMed ID: 17904457
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.